The company's manufacturing system, the Cell Shuttle, is set to be the solution needed to ensure that cell therapy isn't held back by disjointed, cost-prohibitive, and failure-prone procedures. This "factory in a box" houses the instruments needed to handle cells and turn them into therapies and could be market ready by 2024.

The potential for expansion in this niche is massive, as only 10% of the required manufacturing capacity for this field exists today. Cellares is therefore tapping into this market with a robust, cost-effective solution. Its automation, flexibility, and scalability will be hugely valuable to many businesses. Since the automation of systems in this field can result in a 70% cost reduction, this gives the company a competitive edge in a sector that is set to heat up soon.